NCT00054808
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- Genta Berkeley Heights, New Jersey, United States
Clinical trial condition
Refractory Lymphoma
Explore clinical trials studying Refractory Lymphoma. Study availability and eligibility vary by location and protocol.
55 public trials
9 recruiting studies
Refractory Lymphoma trial results
Active, Not Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Thomas Hospital Fairhope, Alabama, United States
- Mobile Infirmary Medical Center Mobile, Alabama, United States
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
Active, Not Recruiting
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
NCT04439227
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
NCT06390826
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
NCT06385483
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
NCT06390839
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hemic and Lymphatic Diseases, +9 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
NCT04439318
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
NCT04439357
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
NCT04439201
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematologic Diseases, +13 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, Not Recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States